DexCom Inc Asset Resilience Ratio
DexCom Inc asset resilience ratio. DexCom Inc (DXCM) has an Asset Resilience Ratio of 19.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DexCom Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DexCom Inc (2005–2025)
Asset resilience ratio of DexCom Inc from 2005 to 2025. This chart shows how DexCom Inc's Asset Resilience Ratio has changed over time. Read DexCom Inc (DXCM) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down DexCom Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DXCM total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.30 Billion | 19.55% |
| Total Liquid Assets | $1.30 Billion | 19.55% |
Asset Resilience Insights
- Good Liquidity Position: DexCom Inc maintains a healthy 19.55% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
DexCom Inc Industry Peers by Asset Resilience Ratio
Compare DexCom Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
DexCom Inc Asset Resilience Ratio by Year (2005–2025)
DexCom Inc asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for DexCom Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.05% | $1.08 Billion | $6.34 Billion | -13.38pp |
| 2024-12-31 | 30.43% | $1.97 Billion | $6.48 Billion | -4.01pp |
| 2023-12-31 | 34.44% | $2.16 Billion | $6.26 Billion | +0.80pp |
| 2022-12-31 | 33.64% | $1.81 Billion | $5.39 Billion | -0.38pp |
| 2021-12-31 | 34.03% | $1.68 Billion | $4.93 Billion | -10.03pp |
| 2020-12-31 | 44.05% | $1.89 Billion | $4.29 Billion | -1.34pp |
| 2019-12-31 | 45.39% | $1.09 Billion | $2.40 Billion | +32.42pp |
| 2018-12-31 | 12.97% | $248.60 Million | $1.92 Billion | +1.13pp |
| 2017-12-31 | 11.85% | $107.10 Million | $904.10 Million | +4.60pp |
| 2016-12-31 | 7.25% | $29.20 Million | $402.80 Million | -2.72pp |
| 2015-12-31 | 9.97% | $29.10 Million | $292.00 Million | +3.57pp |
| 2014-12-31 | 6.39% | $11.80 Million | $184.60 Million | -2.91pp |
| 2013-12-31 | 9.31% | $11.40 Million | $122.50 Million | -29.00pp |
| 2012-12-31 | 38.30% | $40.60 Million | $106.00 Million | -27.57pp |
| 2011-12-31 | 65.87% | $79.36 Million | $120.47 Million | +11.15pp |
| 2010-12-31 | 54.72% | $42.22 Million | $77.16 Million | +2.66pp |
| 2009-12-31 | 52.06% | $24.44 Million | $46.95 Million | +19.67pp |
| 2008-12-31 | 32.39% | $14.37 Million | $44.37 Million | -20.95pp |
| 2007-12-31 | 53.34% | $41.21 Million | $77.26 Million | -2.96pp |
| 2006-12-31 | 56.30% | $36.34 Million | $64.55 Million | +32.89pp |
| 2005-12-31 | 23.41% | $13.28 Million | $56.73 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more